• Profile
Close

Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: An open-label, randomised controlled trial

The Lancet Infectious Diseases Jun 04, 2018

Zaman K, et al. - Researchers investigated the effect of two dosed of monovalent type 2 oral poliovirus vaccine (mOPV2) on the type 2 immune response by varying the time interval between mOPV2 doses and inactivated poliovirus vaccine (IPV) co-administration with mOPV2 in a randomised, controlled, parallel, open-label, non-inferiority, inequality trial at two study clinics in Dhaka, Bangladesh. Between Dec 7, 2015, and Jan 5, 2016, 760 infants were randomly assigned to receive two mOPV2 doses at intervals of 1 week (n=191), 2 weeks (n=191), 4 weeks (n=188), or 4 weeks plus IPV (n=190). Outcomes suggested that administration of mOPV2 at short intervals does not interfere with its immunogenicity. Poliovirus type 2 immune response was not enhanced by the addition of IPV to the first mOPV2 dose.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay